Press Release

ZEISS invests in Odne to transform root canal treatments

Funding will enable acceleration of US market entry and commercialization of new Root Preservation Therapy technology.

12 June 2025

Oberkochen, Germany | 12 June 2025 | ZEISS Group

Odne, a Swiss dental start-up, has announced that it has raised 4.2 million Swiss francs in a Series A1 funding round. ZEISS Ventures supported this round, alongside existing investors and a group of private and dental investors. With FDA clearance for OdneClean, OdneCure, and OdneFill, and a successful launch at AAE 2025, the investment will enable the company to accelerate commercialization and US market entry of its game-changing technology for Root Preservation Therapy (RPT) starting with OdneClean.

Product image of the Odne product portfolio. White and blue packaging in white environs. — The Odne product portfolio.

Founded in 2018 as a spin-out from ETH Zurich and EPFL, Odne is a Swiss dental technology company focused on redefining endodontic treatment through its innovative RPT workflow. Its OdneClean device, based on hydrodynamic cavitation using sterile water, enables efficient debridement and disinfection of complex root canal geometries, derisking and accelerating procedures for both specialists and general dentists.

“It is amazing to see the positive response of the endodontic community to OdneClean. It is an affordable, high-tech solution for debridement and disinfection of the root canal – efficiently cleaning complex root canal geometries, derisking and accelerating procedures. The solution addresses more clinical challenges than we initially intended to cover and serves as an easy-to-use, must-have for any dentist. The complete Odne RPT workflow, enabling minimal invasive treatment, combining advanced irrigation with sterile water and simple light-cured obturation of complex root morphologies will become the gold-standard,” states Dr. Andreas Schmocker, CEO & Co-Founder of Odne.

“We strongly believe that Odne’s RPT workflow has the potential to fundamentally transform endodontic treatment, benefiting both specialized endodontists and general practitioners,” says Prof. Dr. Boris Hofmann, Head of ZEISS Ventures.

Complications arising from inadequate root canal cleaning remain a major clinical challenge in endodontics, contributing to treatment failures and retreatments. Odne’s solution aims to raise the standard of care while improving outcomes for patients and dentists alike.

Press Contact Julian Bosch

Corporate Brand, Communications and Public Affairs
ZEISS Group

About ZEISS

ZEISS is an internationally leading technology company in the optics and optoelectronics industry. The ZEISS Group generated annual revenue totaling around 11 billion euros in its four segments Industrial Quality & Research, Medical Technology, Consumer Markets and Semiconductor Manufacturing Technology (updated: 30 September 2024).

For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for life sciences and materials research, as well as medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare and Industry 4.0 as well as a strong brand, ZEISS is shaping technological progress and, through its solutions, is extending the horizon of the world of optics and associated areas. ZEISS' significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 14% of its revenue in research and development work – ZEISS has a long tradition of high expenditure in these areas. This also represents the company's investment in the future.

With more than 46,555 employees, ZEISS operates in around 50 countries with more than 60 sales and service sites, 40 research and development sites and 35 production sites worldwide (as of 31 March 2025). The headquarters of the company, which was founded in Jena in 1846, is located in Oberkochen, Germany. The Carl Zeiss Foundation, one of Germany’s largest foundations committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

About ZEISS Ventures
ZEISS Ventures, the corporate venture capital arm of the ZEISS Group, makes investments and actively manages a portfolio of start-up companies. The goal is to invest in and partner with deep-tech start-ups, which go beyond ZEISS' core business and have the potential to disrupt and innovate existing technologies and business models. ZEISS Ventures seeks to empower start-ups not only with financial support but also with access to its resources, expertise, and global network as a deep-tech corporation to foster and accelerate the development and commercialization of market-shaping innovations. For more information, please visit www.zeiss.com/ventures

About Odne
Odne (Odne AG and Odne Inc) is a Swiss-US dental start-up that has its roots in a groundbreaking collaboration between two renowned universities: the Swiss Federal Institutes of Technology in Lausanne and Zürich (EPFL & ETH Zürich). Founded in 2018, Odne`s journey began by licensing cutting-edge technology assets from these esteemed institutes.

To serve the US endodontics specialist market, Odne has founded Odne Inc, USA. The team of Odne is evolving, incorporating experienced and well-connected dental experts, building training, service, marketing, and sales.

Odne represents a harmonious synergy of Swiss precision and academic excellence. The company is committed to pioneering the future of endodontics through advanced technology and innovative solutions. Endodontics, the field of dental medicine that deals with root canal treatments, has been marred by complexity and unpredictability. Odne AG is on a mission to change that.
Root canal treatments have long posed challenges for dentists, with traditionally low success rates ranging from 46% to 91%. With over 60 million annual treatments worldwide, these failures result in significant healthcare costs. Odne's technology platform addresses these issues by offering innovative treatment options for both dentists and their patients. Besides the launch of OdneClean in the US, Odne will continue its priority access program for OdneFill – the first light-curing root canal filling material, while completing the clinical studies.

For more information, visit www.odne.co